A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar Lines

PHASE3CompletedINTERVENTIONAL
Enrollment

309

Participants

Timeline

Start Date

March 8, 2022

Primary Completion Date

February 1, 2023

Study Completion Date

February 1, 2023

Conditions
Glabellar Lines
Interventions
DRUG

AGN-151586

Intramuscular Injection

DRUG

Placebo

Intramuscular Injection

Trial Locations (17)

22209

SkinDC /ID# 238988, Arlington

28403

Wilmington Dermatology Center /ID# 233935, Wilmington

29407

Clinical Research Center of the Carolinas /ID# 239064, Charleston

78660

Austin Institute for Clinical Research /ID# 238989, Pflugerville

90277

Marcus Facial Plastic Surgery /ID# 241703, Redondo Beach

85255-4134

Clear Dermatology & Aesthetics Center /ID# 238990, Scottsdale

92663-3311

Steve Yoelin MD Medical Assoc. Inc /ID# 243197, Newport Beach

06880-5369

DMR Research PLLC /ID# 239061, Westport

30328-4402

Kavali Plastic Surgery /ID# 244808, Atlanta

70809-2725

Delricht Research - 10154 Jefferson /ID# 244890, Baton Rouge

21030-3216

Maryland Dermatology Laser, Skin, & Vein Institute /ID# 239067, Hunt Valley

84120-2058

Kalo Clinical Research /ID# 247279, West Valley City

V5Z 1H2

YVR Aesthetics Training & Study Centre /ID# 241858, Vancouver

V6H 4E1

Pacific Derm /ID# 239654, Vancouver

K9A 0Z4

Dr Melinda Gooderham Medicine Profession /ID# 239657, Cobourg

L6J 7W5

The Centre for Clinical Trials /ID# 245873, Oakville

H7N 6L2

Clinique D /ID# 239653, Laval

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allergan

INDUSTRY

NCT05248880 - A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar Lines | Biotech Hunter | Biotech Hunter